KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

Company Overview - KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare and severe eye diseases [3] - The company utilizes a proprietary mesenchymal stem cell secretome (MSC-S) platform for its investigational therapies [3] Leadership Announcement - Todd Bazemore has been appointed as President and Chief Executive Officer (CEO) of KALA BIO, having served as interim CEO since February 2025 [1][2] - Bazemore brings over 30 years of leadership experience in the biopharmaceutical industry, particularly in rare diseases [1][2] Clinical Development - KALA's lead product candidate, KPI-012, is currently in clinical development for persistent corneal epithelial defect (PCED), a rare disease with no FDA-approved treatments addressing all underlying causes [3] - KPI-012 has received Orphan Drug and Fast Track designations from the U.S. FDA [3] - The company is preparing for the upcoming readout of the Phase 2b CHASE trial of KPI-012, which is seen as a pivotal moment for potential commercialization [2] Strategic Focus - The company aims to transition from a clinical-stage biotechnology firm to a fully integrated organization with commercial capabilities [2] - KALA is also exploring the potential of KPI-012 for other rare corneal diseases and has initiated preclinical studies for retinal degenerative diseases [3]